| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
|
Clin Cancer Res
|
2005
|
2.21
|
|
2
|
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
|
Oncology
|
2007
|
1.70
|
|
3
|
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
|
Clin Cancer Res
|
2011
|
1.53
|
|
4
|
Minilaparotomy in early stage endometrial cancer: an alternative to standard and laparoscopic treatment.
|
Gynecol Oncol
|
2002
|
1.45
|
|
5
|
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
|
J Clin Oncol
|
2011
|
1.36
|
|
6
|
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer.
|
Immunology
|
2007
|
1.22
|
|
7
|
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.
|
Mol Pharmacol
|
2003
|
1.20
|
|
8
|
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.
|
Ann Surg Oncol
|
2006
|
1.19
|
|
9
|
MiR-200c and HuR in ovarian cancer.
|
BMC Cancer
|
2013
|
1.18
|
|
10
|
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
|
Clin Cancer Res
|
2009
|
1.17
|
|
11
|
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
|
J Cell Physiol
|
2012
|
1.15
|
|
12
|
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
|
Am J Obstet Gynecol
|
2008
|
1.12
|
|
13
|
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience.
|
Surg Endosc
|
2014
|
1.10
|
|
14
|
Pseudo-Meigs' syndrome associated with malignant struma ovarii: a case report.
|
Gynecol Oncol
|
2004
|
1.10
|
|
15
|
Stereotactic radiotherapy in recurrent gynecological cancer: a case series.
|
Oncol Rep
|
2009
|
1.06
|
|
16
|
HuR regulates beta-tubulin isotype expression in ovarian cancer.
|
Cancer Res
|
2010
|
1.04
|
|
17
|
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.
|
Mol Cancer Ther
|
2008
|
1.04
|
|
18
|
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.
|
Cancer Immunol Immunother
|
2009
|
1.02
|
|
19
|
Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients.
|
Radiother Oncol
|
2008
|
1.01
|
|
20
|
Conservative surgical management of stage IA endometrial carcinoma for fertility preservation.
|
Fertil Steril
|
2009
|
1.00
|
|
21
|
Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis.
|
BMC Cancer
|
2013
|
0.96
|
|
22
|
Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.95
|
|
23
|
Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire.
|
Immunology
|
2003
|
0.95
|
|
24
|
Novel targets for VEGF-independent anti-angiogenic drugs.
|
Expert Opin Investig Drugs
|
2012
|
0.95
|
|
25
|
Estrogen receptor beta in cancer: an attractive target for therapy.
|
Curr Pharm Des
|
2012
|
0.95
|
|
26
|
Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients.
|
Oncology
|
2003
|
0.95
|
|
27
|
Forward planned intensity modulated radiotherapy (IMRT) for whole breast postoperative radiotherapy. Is it useful? When?
|
J Appl Clin Med Phys
|
2011
|
0.94
|
|
28
|
Femur metastasis in carcinoma of the uterine cervix: a rare entity.
|
Arch Gynecol Obstet
|
2009
|
0.93
|
|
29
|
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
|
BMC Cancer
|
2008
|
0.93
|
|
30
|
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
|
Gynecol Oncol
|
2011
|
0.93
|
|
31
|
Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients.
|
Gynecol Oncol
|
2004
|
0.92
|
|
32
|
Color Doppler sonographic features of a Krukenberg tumor in pregnancy.
|
J Ultrasound Med
|
2009
|
0.92
|
|
33
|
The use of contrasted transvaginal sonography in the diagnosis of gynecologic diseases: a preliminary study.
|
J Ultrasound Med
|
2005
|
0.92
|
|
34
|
Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy.
|
Clin Ther
|
2011
|
0.91
|
|
35
|
Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report.
|
Diagn Pathol
|
2012
|
0.90
|
|
36
|
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
|
Crit Rev Oncol Hematol
|
2008
|
0.90
|
|
37
|
Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma.
|
Cancer
|
2004
|
0.89
|
|
38
|
Neuroendocrine stress response in patients undergoing benign ovarian cyst surgery by laparoscopy, minilaparotomy, and laparotomy.
|
J Am Assoc Gynecol Laparosc
|
2003
|
0.89
|
|
39
|
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
|
Expert Opin Investig Drugs
|
2009
|
0.87
|
|
40
|
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.
|
BMC Cancer
|
2011
|
0.87
|
|
41
|
Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy.
|
Gynecol Oncol
|
2008
|
0.87
|
|
42
|
Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
|
Cancer Chemother Pharmacol
|
2002
|
0.86
|
|
43
|
Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?
|
PLoS One
|
2012
|
0.86
|
|
44
|
Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.
|
Int J Gynecol Cancer
|
2011
|
0.85
|
|
45
|
3D-Conformal versus intensity-modulated postoperative radiotherapy of vaginal vault: A dosimetric comparison.
|
Med Dosim
|
2009
|
0.85
|
|
46
|
Standardized sample preparation phases for a quantitative measurement of plasma peptidome profiling by MALDI-TOF.
|
J Proteomics
|
2010
|
0.85
|
|
47
|
Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.84
|
|
48
|
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1).
|
Gynecol Oncol
|
2010
|
0.84
|
|
49
|
Vulvar squamous cell carcinoma with sarcoma-like stroma: a case report and review of the literature.
|
Diagn Pathol
|
2011
|
0.84
|
|
50
|
Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome.
|
BMC Cancer
|
2008
|
0.83
|
|
51
|
Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
|
Int J Gynecol Cancer
|
2014
|
0.83
|
|
52
|
Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study.
|
Am J Clin Oncol
|
2008
|
0.82
|
|
53
|
The role of sonographic examination in the follow-up of gynecological neoplasms.
|
Gynecol Oncol
|
2005
|
0.80
|
|
54
|
Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures.
|
Acta Oncol
|
2012
|
0.80
|
|
55
|
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
|
Crit Rev Oncol Hematol
|
2009
|
0.80
|
|
56
|
Expression and subcellular localization of CRH and its receptors in human endometrial cancer.
|
Mol Cell Endocrinol
|
2009
|
0.80
|
|
57
|
Treatment of cervical cancer in Italy: strategies and their impact on the women.
|
Vaccine
|
2009
|
0.80
|
|
58
|
Safety and effectiveness of coadministration of intrathecal sufentanil and morphine in hyperbaric bupivacaine-based spinal anesthesia for cesarean section.
|
J Opioid Manag
|
2009
|
0.79
|
|
59
|
Corticotropin-releasing hormone receptor-1 in human endometrial cancer.
|
Oncol Rep
|
2006
|
0.79
|
|
60
|
Gemcitabine: current role and future options in the treatment of ovarian cancer.
|
Crit Rev Oncol Hematol
|
2003
|
0.79
|
|
61
|
Short-course accelerated radiotherapy in palliative treatment of advanced pelvic malignancies: a phase I study.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.79
|
|
62
|
Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome.
|
Tumori
|
2005
|
0.79
|
|
63
|
RON and cisplatin resistance in ovarian cancer cell lines.
|
Oncol Res
|
2010
|
0.79
|
|
64
|
Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial.
|
Oncol Lett
|
2013
|
0.79
|
|
65
|
Novel VEGF-independent strategies targeting tumor vasculature: clinical aspects.
|
Curr Pharm Des
|
2012
|
0.78
|
|
66
|
Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison.
|
Acta Oncol
|
2013
|
0.78
|
|
67
|
Dietary soy modulation of biochemical parameters in DMBA-induced mammary tumors.
|
Cancer Lett
|
2002
|
0.78
|
|
68
|
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.
|
Oncology
|
2002
|
0.78
|
|
69
|
Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study.
|
Int J Gynecol Cancer
|
2015
|
0.78
|
|
70
|
Concurrent 5-fluorouracil, mitomycin C and radiation, with or without brachytherapy, in recurrent endometrial cancer: a scoring system to predict clinical response and outcome.
|
Tumori
|
2005
|
0.78
|
|
71
|
Concomitant boost plus large-field preoperative chemoradiation in locally advanced uterine cervix carcinoma: Phase II clinical trial final results (LARA-CC-1).
|
Gynecol Oncol
|
2012
|
0.77
|
|
72
|
Pharmacotherapy of cervical cancer.
|
Expert Opin Pharmacother
|
2010
|
0.77
|
|
73
|
Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters.
|
Hum Reprod
|
2004
|
0.77
|
|
74
|
Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
|
Menopause
|
2016
|
0.77
|
|
75
|
Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.
|
Gynecol Oncol
|
2011
|
0.76
|
|
76
|
Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome.
|
Int J Gynecol Cancer
|
2009
|
0.76
|
|
77
|
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
|
BMC Cancer
|
2014
|
0.76
|
|
78
|
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1).
|
Am J Clin Oncol
|
2010
|
0.76
|
|
79
|
Angiographic power 3-dimensional quantitative analysis in gynecologic solid tumors: feasibility and reproducibility.
|
J Ultrasound Med
|
2004
|
0.75
|
|
80
|
Re: A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment by P. Morice et al.
|
Gynecol Oncol
|
2005
|
0.75
|
|
81
|
Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.
|
Nanomedicine (Lond)
|
2014
|
0.75
|
|
82
|
Solitary pancreatic lymph node metastasis from carcinoma of the breast: case report.
|
Diagn Pathol
|
2010
|
0.75
|
|
83
|
Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study.
|
Gynecol Oncol
|
2002
|
0.75
|
|
84
|
3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I-II study (ADA-RT-1).
|
Gynecol Oncol
|
2010
|
0.75
|
|
85
|
Postoperative intensity-modulated radiotherapy in low-risk endometrial cancers: final results of a Phase I study.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.75
|
|
86
|
Doppler velocimetry and cytofluorimetric analysis in uterine myomas.
|
Gynecol Obstet Invest
|
2003
|
0.75
|
|
87
|
Investigational agents against platinum-resistant ovarian cancer.
|
Expert Opin Investig Drugs
|
2007
|
0.75
|
|
88
|
Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
|
Ann Surg Oncol
|
2014
|
0.75
|
|
89
|
Pelvic relapses of uterine neoplasms: transvaginal sonographic and Doppler features.
|
Gynecol Oncol
|
2004
|
0.75
|
|
90
|
Prognostic significance and clinical relevance of the expression of the HER family of type I receptor tyrosine kinases in human laryngeal squamous cell carcinoma.
|
Eur J Cancer
|
2010
|
0.75
|
|
91
|
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.
|
Oncologist
|
2013
|
0.75
|
|
92
|
Carboplatin-based neoadjuvant treatment with peripheral blood stem cell and growth factor support in locally advanced cervical cancer patients with bulky metastatic lymph nodes.
|
Eur J Obstet Gynecol Reprod Biol
|
2006
|
0.75
|
|
93
|
Active Breathing Coordinator in adjuvant three-dimensional conformal radiotherapy of early stage breast cancer: a feasibility study.
|
Tumori
|
2010
|
0.75
|
|
94
|
Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis.
|
Hum Reprod
|
2005
|
0.75
|
|
95
|
Targeting molecular pathways in human malignancy: current status and future development.
|
Curr Pharm Des
|
2012
|
0.75
|
|
96
|
Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility.
|
Oncology
|
2004
|
0.75
|
|
97
|
Intratumoral color Doppler analysis in endometrial carcinoma: is it clinically useful?
|
Gynecol Oncol
|
2003
|
0.75
|